

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA MEDICAL SYSTEM HOLDINGS LIMITED

康哲藥業控股有限公司*

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 867)

Voluntary and Business Update Announcement The Singapore Manufacturing Plant Matter and the CDMO Collaboration of an Associate

China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that on 27 December 2023, the Company’s Singapore associate PharmaGend Global Medical Services Pte. Ltd. (“PharmaGend”) entered into a lease agreement with PERPETUAL (ASIA) LIMITED for the building and property located in Tuas, Singapore which will serve as the site for PharmaGend to carry out pharmaceutical formulation, finishing and packaging business; on 29 December 2023, PharmaGend completed the purchase of certain production machines and equipment from Strides Pharma Global Pte. Ltd. (“Strides Pharma”) and certain contract manufacturing organization (CMO) agreements and service agreements entered into between and by PharmaGend and Strides Pharma came into effect on the same day (the aforementioned matters are collectively referred to as the “Singapore Manufacturing Plant Matter”).

Previously, on 20 October 2023, CMS MEDICAL VENTURE PTE. LTD. (a wholly-owned subsidiary of the Company) (“CMS Medical Venture”), Rxilient Health Pte. Ltd. (a non-wholly owned subsidiary of the Company) (“Rxilient”), Pharmaron (Hong Kong) International Limited (a wholly-owned subsidiary of Pharmaron Beijing Co., Ltd. (stock code: 300759.SZ/3759.HK)) (“Pharmaron”), HEALTHY GOAL LIMITED (“Legend Fund”) and Rxilient Biohub Pte. Ltd. (a non-wholly owned subsidiary of the Company at that time) (“Rxilient Biohub”) entered into a share subscription and shareholders agreement, pursuant to

which CMS Medical Venture, Rxilient, Pharmaron and Legend Fund agreed to increase the registered capital of Rxilient Biohub from US\$200,000 to US\$30,000,000 (the “Capital Increase”); upon the completion of the Capital Increase on 15 December 2023, CMS Medical Venture and Rxilient hold a total of 45% of the enlarged registered capital of Rxilient Biohub, and the financial results of Rxilient Biohub would no longer be consolidated into the consolidated financial statements of the Group and Rxilient Biohub became an associate of the Company; on 20 December 2023, Rxilient Biohub changed its name to PharmaGend.

In the future, CMS Medical Venture, Rxilient, Pharmaron and Legend Fund will continue to carry out collaboration on formulation contract development and manufacturing organization (formulation CDMO) business in Singapore through PharmaGend (the “CDMO Collaboration”).

REASONS FOR AND BENEFITS OF THE SINGAPORE MANUFACTURING PLANT MATTER AND THE CDMO COLLABORATION

Based on more than 30 years of global investment and acquisition experience and proven commercialization capabilities, the Group actively implements an internationalization strategy starting from Southeast Asia with the mindset of openness and collaboration and is actively laying out overseas supply chains and production capabilities. The Singapore manufacturing plant has advanced manufacturing machines and equipment and first-class infrastructure. It had been approved by Health Sciences Authority of Singapore (HSA), U.S. Food and Drug Administration (FDA) and Therapeutic Goods Administration of Australia (TGA). The Singapore Manufacturing Plant Matter will be able to optimize the layout of the Group's overseas supply chain and production capacity, ensure the safety of the overseas supply chain and improve supply stability. In addition, it will help the Group to carry out product cooperation with global partners in the future and promote more cooperation opportunities.

The Group is gradually building up an operational structure integrating product introduction, development, manufacture, formulation CDMO, marketing and promotion in Southeast Asia to create an open platform that covers core operational stages of products. The CDMO Collaboration is of great significance to the Group in accelerating its business development in Southeast Asia. Relying on Singapore's advantages in location, policy, law and talents, the Group will synergize with Pharmaron's rich global R&D and international CDMO operation capabilities and experience as well as Legend Fund's capital market influence to promote the R&D and production of products in the Southeast Asian market, enable biotech and pharmaceutical companies in Europe, America, Japan and China to quickly enter the

Southeast Asian market and build a "bridgehead" for global pharmaceutical companies in Southeast Asia.

Having considered the above, the directors of the Company (the "Directors") are of the view that the Singapore Manufacturing Plant Matter and the CDMO Collaboration are in the interests of the Company and its shareholders as a whole.

LISTING RULES IMPLICATIONS

To the best of the Directors' knowledge, information and belief after having made all reasonable enquiries, the Capital Increase, the Singapore Manufacturing Plant Matter and the CDMO Collaboration do not constitute connected transactions or notifiable transactions of the Company under the Rules Governing the Listing of the Securities on The Stock Exchange of Hong Kong Limited.

This announcement is made on a voluntary basis by the Company and aims to inform potential investors and shareholders of the Company of the latest business developments of the Group.

By order of the Board
China Medical System Holdings Limited
Lam Kong
Chairman

Hong Kong, 29 December 2023

As at the date of the announcement, the directors of the Company comprise (i) Mr. Lam Kong, Mr. Chen Hongbing and Ms. Chen Yanling as executive directors; and (ii) Mr. Leung Chong Shun, Ms. Luo Laura Ying and Mr. Fung Ching Simon as independent non-executive directors.